Serum levels of γ-glutamyl transferase are associated with cardiovascular disease in obstructive sleep apnea syndrome

Abstract

BACKGROUND AND OBJECTIVES: Obstructive sleep apnea syndrome (OSAS) significantly increases the risk of cardiovascular disease (CVD). γ-glutamyl transferase (GGT) is a new marker for predicting CVD. The aim of this study was to evaluate the relationship of serum GGT levels with cardiovascular event, severity of OSAS, and polysomnographic parameters in patients with OSAS. DESIGN AND SETTINGS: This was a retrospective, cross-sectional study conducted between January 2011 and March 2013 (Gaziosmanpasa University, Faculty of Medicine, Tokat, Turkey). METHODS: We performed a retrospective study. Patients were divided according to their apnea-hypopnea index (AHI) scores into OSAS negative (AHI 30, Group 4) groups. The presence of heart failure, coronary artery disease, or arrhythmia was defined as CVD. RESULTS: A total of 320 patients, with a mean age of 50.2 (10.8) years, were included in this study. There were 47, 68, 58, and 147 patients in Groups 1, 2, 3, and 4, respectively. Serum GGT levels were significantly different between groups (Group 1: 25.24 [14.95]; Group 2: 28.03 [11.92]; Group 3: 32.82 [18.18], and Group 4: 40.41 [31.90] mg/dL, P<.001). Besides, serum GGT levels were significantly correlated with AHI, oxygen desaturation index, and average and minimum O2 saturation values (P<.05). Serum GGT levels were significantly higher in patients with CVD compared with those without (P<.05). Multiple regression analysis demonstrated that independent predictors of CVD were serum GGT and low-density lipoprotein-cholesterol levels, age, and body mass index in patients with OSAS. CONCLUSION: GGT level is an important predictor for CVD in patients with OSAS. The effectiveness of continuous positive airway pressure therapy on CVD and GGT levels should be investigated.